Head-To-Head Review: CG Oncology (NASDAQ:CGON) & BioCardia (NASDAQ:BCDA)

BioCardia (NASDAQ:BCDA) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for BioCardia and CG Oncology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	0	1	1	0	2.50
CG Oncology	0	0	5	0	3.00

BioCardia presently has a consensus price target of $60.00, suggesting a potential upside of 1,906.69%. CG Oncology has a consensus price target of $64.00, suggesting a potential upside of 101.77%. Given BioCardia’s higher possible upside, analysts plainly believe BioCardia is more favorable than CG Oncology.

Insider & Institutional Ownership

20.6% of BioCardia shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 20.0% of BioCardia shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares BioCardia and CG Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioCardia	-2,208.76%	-3,638.68%	-261.66%
CG Oncology	N/A	N/A	N/A

Earnings & Valuation

This table compares BioCardia and CG Oncology’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$480,000.00	11.34	-$11.57 million	($7.05)	-0.42
CG Oncology	$200,000.00	10,569.10	-$48.61 million	N/A	N/A

BioCardia has higher revenue and earnings than CG Oncology.

Summary

CG Oncology beats BioCardia on 7 of the 11 factors compared between the two stocks.

About BioCardia

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. BioCardia, Inc. is based in Sunnyvale, California.

About CG Oncology

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.